Skip to main content

Table 1 Correlation among clinicopathologic status and the expression of miR-320a or integrin β3 in SACC patients

From: MiR-320a acts as a prognostic factor and Inhibits metastasis of salivary adenoid cystic carcinoma by targeting ITGB3

A. Correlation among clinicopathologic status and the expression of miR-320a or integrin β3 in SACC patients of Sun Yat-sen University
Characteristics miR-320a (%) Integrin β3 (%)
  No. of low expression No. of high expression P No. of low expression No. of high expression P
Sex    0.905    0.097
Male 83 (61.9) 51 (38.1)   45 (33.6) 89 (66.4)  
Female 106 (63.1) 62 (36.9)   73 (43.5) 95 (56.5)  
Age    0.153    0.814
<50 82 (58.2) 59 (41.8)   54 (38.3) 87 (61.7)  
≥50 107 (66.5) 54 (33.5)   64 (39.8) 97 (60.2)  
Tumor Size    0.801    0.319
T1-2 125 (61.9) 77 (38.1)   83 (41.1) 119 (58.9)  
T3-4 64 (64.0) 36 (36.0)   35 (35.0) 65 (65.0)  
Node metastasis    0.029    0.032
N0 154 (59.9) 103 (40.1)   107 (41.6) 150 (58.4)  
N1 35 (77.8) 10 (22.2)   11 (24.4) 34 (75.6)  
TNM stage    0.074    0.044
I-II 95 (57.9) 69 (42.1)   73 (44.5) 91 (55.5)  
III-IV 94 (68.1) 44 (31.9)   45 (32.6) 93 (67.4)  
Distant Metastasis    <0.001    0.001
No 90 (52.3) 82 (47.7)   81 (47.1) 91 (52.9)  
Yes 99 (76.2) 31 (23.8)   37 (28.5) 93 (71.5)  
Status    0.002    0.009
Survival 84 (54.2) 71 (45.8)   72(46.5) 83 (53.5)  
Death 105 (71.4) 42 (28.6)   46(31.3) 101 (68.7)  
B. Correlation among clinicopathologic status and the expression of miR-320a or integrin β3 in SACC patients of Central South University
Sex    0.496    0.865
Male 53 (66.2) 27 (33.8)   29 (36.2) 51 (63.8)  
Female 41 (60.3) 27 (39.7)   26 (38.2) 42 (61.8)  
Age    0.170    0.609
<50 47 (58.0) 34 (42.0)   32 (39.5) 49 (60.5)  
≥50 47 (70.1) 20 (29.9)   23 (34.3) 44 (65.7)  
Tumor Size    0.601    0.861
T1-2 60 (65.2) 32 (34.8)   35 (38.0) 57 (62.0)  
T3-4 34 (60.7) 22 (39.3)   20 (35.7) 36 (64.3)  
Node metastasis    0.811    0.469
N0 80 (63.0) 47 (37.0)   49 (38.6) 78 (61.4)  
N1-N2 14 (66.7) 7 (33.3)   6 (28.6) 15 (71.4)  
TNM stage    0.392    0.608
I-II 56 (66.7) 28 (33.3)   33 (39.3) 51 (60.7)  
III-IV 38 (59.4) 26 (40.6)   22 (34.4) 42 (65.6)  
Distant Metastasis    0.001    0.004
No 42 (51.2) 40 (48.8)   39 (47.6) 43 (52.4)  
Yes 52 (78.8) 14 (21.2)   16 (24.2) 50 (75.8)  
Status    0.004    0.017
Survival 37 (51.4) 35 (48.6)   34 (47.2) 38 (52.8)  
Death 57 (75.0) 19 (25.0)   21 (27.6) 55 (72.4)